ArticlePloS one2026
Targeted transferosomal delivery of cetirizine: A new approach to alopecia management.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAndrogenetic alopecia is common in males and females; its prevalence increases with age. It affects the social life of individuals worldwide. The main problem associated with conventional minoxidil treatment is the risk of facial hypertrichosis. Cetirizine (CET), an antihistamine, may induce hair growth by increasing prostaglandin E2 expression. Therefore, Objectives: This study aimed to incorporate several CET formulations into transferosomes (TFS) and determine their optimal physicochemical properties. The optimal formulation was evaluated for its growth-promoting potential in vivo.
methodsThe effect of CET-TFS was assessed by observing hair growth and quantifying insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) mRNA and protein levels in mice.
resultsCET-TFS significantly enhanced hair growth in mice and stimulated high IGF-1 and VEGF mRNA and protein levels.
conclusionThese findings suggest that CET-TFS is a promising alternative to traditional hair growth medications. Additional toxicity and histopathological studies are required to confirm its suitability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.